Brain Health Insights: Alzheimer's Prevention Research, Explained

Articles on brain health, Alzheimer's prevention, genetics, lifestyle medicine, and the science of cognitive longevity — written for patients who want to understand, not just be told what to do.

Genetics & Risk

What Does My APOE Genotype Mean? From e2/e2 to e4/e4

A genotype-by-genotype guide to APOE results from 23andMe or a lab: how common each of the six genotypes is, how much each changes Alzheimer’s risk by ancestry and sex, why e4/e4 is different, what e2/e2 means for cholesterol, and what to do next.

October 2026
Alzheimer's Prevention

I Have Mild Cognitive Impairment. Is It Alzheimer’s, and What Happens Next?

Mild cognitive impairment is a measurable decline in thinking with independence intact. It has many causes, not only Alzheimer’s. What the diagnosis means, how often it progresses or reverses, the workup that finds the cause, and what helps.

October 2026
Alzheimer's Prevention

Who Qualifies for Leqembi or Kisunla, and What Does APOE4 Mean for ARIA Risk?

Leqembi (lecanemab) and Kisunla (donanemab) are for MCI or mild Alzheimer’s dementia with confirmed amyloid. What the trials showed in plain numbers, who is excluded, and how APOE4 raises the risk of ARIA brain swelling.

October 2026
Biomarkers

Which Alzheimer’s Blood Tests Are FDA-Cleared, and Should You Get One?

The FDA has now cleared four Alzheimer’s blood tests: Lumipulse, Elecsys pTau181, PrecivityAD2 and Elecsys pTau217. A neurologist compares what each measures, who it is cleared for, how results are reported, and whether testing makes sense if you have no symptoms.

October 2026
Biomarkers

My Amyloid Beta 42/40 Ratio Is Low. Do I Have Alzheimer’s?

A low amyloid beta 42/40 ratio on a blood test suggests amyloid plaques may be present, but it is not a dementia diagnosis. A neurologist explains lab cutoffs, why the ratio is less accurate than p-tau217, what can skew it, and what to do next.

October 2026
Brain Imaging

My MRI Shows White Matter Hyperintensities. Does That Mean Dementia?

White matter hyperintensities — often reported as “chronic microvascular ischemic changes” — are extremely common and are not a diagnosis of dementia. A neurologist explains how to read the radiology language, how much burden actually matters, what causes them, and the one thing proven to slow their progression.

October 2026
Women's Brain Health

Perimenopause, Menopause, and Memory Loss: Why It Happens and What Actually Helps

Memory and concentration problems during perimenopause are real, common, and usually temporary. A neurologist explains what the hormonal transition does to the brain, which treatments help, what hormone therapy can and cannot do for memory, and the specific signs that mean something other than menopause is going on.

September 2026
Genetics & Risk

I Have APOE4 but No Symptoms. What Should I Do Next?

Carrying one or two copies of APOE4 raises Alzheimer’s risk, but it is not a diagnosis and it is not a sentence. A preventive neurologist walks through the practical sequence: confirm the result, understand what one copy versus two actually means, measure the right baselines, and act on the risks that are genuinely modifiable.

August 2026
Biomarkers

My p-tau217 Blood Test Is Positive. Do I Have Alzheimer’s?

A positive p-tau217 blood test means Alzheimer’s-related amyloid changes are likely present in the brain. It does not mean you have dementia, and it does not mean you will. A neurologist explains how to read a positive, borderline, or negative result — and what actually changes next.

August 2026
Alzheimer's Prevention

Lithium and Alzheimer’s: What the Harvard Discovery Does and Doesn’t Mean

A 2025 Harvard study linked lithium deficiency to Alzheimer’s disease. A preventive neurologist explains what the science shows — and why you should not start lithium supplements on your own.

July 2026
Alzheimer's Prevention

Ozempic and Your Brain: What the GLP-1 Trials Actually Showed

Do GLP-1 drugs like Ozempic and Wegovy protect the brain? A preventive neurologist unpacks the 2026 EVOKE trial results and what they actually mean for dementia risk.

July 2026
Alzheimer's Prevention

The Shingles Vaccine and Dementia: A Surprising Connection

Can the shingles vaccine lower your risk of dementia? A preventive neurologist reviews the striking 2024–2025 evidence, including a natural experiment in Wales, and what it means for you.

June 2026
Alzheimer's Prevention

Creatine for Brain Health: Beyond the Gym

Creatine isn’t just for building muscle. A preventive neurologist reviews the evidence for creatine, cognition, menopause, and brain aging — and how to use it sensibly.

May 2026
Alzheimer's Prevention

Early Signs of Alzheimer’s vs. Normal Aging: How to Tell the Difference

Most of us forget where we put our keys. But there is a meaningful difference between normal age-related forgetting and the early changes that signal Alzheimer’s disease. Here is how a preventive neurologist thinks about the distinction — and why recognizing it sooner changes everything.

March 2026
Biomarkers

Blood Tests for Alzheimer’s Risk: What’s Available Now and What They Mean

For decades, confirming Alzheimer’s pathology required expensive PET imaging or an invasive spinal tap. That is changing. A new generation of blood biomarkers can now detect Alzheimer’s-related brain changes years before symptoms appear — and they are beginning to reach clinical practice.

February 2026
Genetics & Risk

What Is APOE4, and What Does It Actually Mean for Your Brain?

APOE4 is the single strongest genetic risk factor for Alzheimer’s. Here’s what it is, what it isn’t, and what you can actually do about it.

January 2026
Lifestyle Medicine

Sleep and Alzheimer’s: What the Research Actually Says

Poor sleep doesn’t just make you tired. It disrupts the brain’s waste clearance system — and the damage accumulates over decades. Here’s what the science says.

December 2025
Prevention Science

The 45%: What Modifiable Risk Factors Mean for Dementia Prevention

The 2024 Lancet Commission identified 14 modifiable risk factors that together account for approximately 45% of dementia cases worldwide. Here’s what that figure actually means, and how it becomes a clinical checklist.

November 2025

Ready to go beyond
reading about it?

A complimentary discovery call is the first step toward a personalized prevention plan built around your biology and goals.

Book Your Discovery Call

Preventive Neurology with Dr. Bilici · Don't wait for symptoms.

Book Your Discovery Call →